Bi’s back; plus changes at Kymera, Immunovia, Apic, Vor, Organogenesis and more

Jingquan Bi was appointed as a deputy director of the Economic Committee of the Chinese People's Political Consultative Conference. He previously served as head of China’s State Drug Administration (now National Medical Products Administration), but resigned in March 2018 amid a vaccines manufacturing scandal (see “Thinking Beyond Bi”).

Kymera Therapeutics Inc. (NASDAQ:KYMR) hired Richard Chesworth as CSO. He joins the protein degradation company from Third Rock Ventures, where he was an entrepreneur in residence, and previously was SVP of research at Epizyme Inc. (NASDAQ:EPZM) in 2010-19...